The second part of our conversation with Craig Burton, MBA, executive director of the Biosimilars Council, a trade and ...

SAN FRANCISCO -- More adults with moderate-to-severe Crohn's disease (CD) reached clinical remission after 6 months on ...

Hims & Hers' “Sick of the System” spot not only generated the highest engagement of all pharma-related ads that aired during ...

There are many stocks with exceptional dividends to check out. Here are three dividend stocks to double up on right now.

Despite the death of its golden goose, AbbVie expects to achieve high single-digit compound annual sales growth to the end of ...

Invest in essential sectors like consumer staples and energy to beat inflation. See why these stocks offer reliable dividends ...

We spoke recently with Craig Burton, MBA, executive director of the Biosimilars Council, a trade and lobbying group for the ...

Artificial intelligence (AI) is transforming various industries as a major investing theme in 2025. The technology's ability ...

Mucinex knocked Vicks off the top spot for monthly TV ad impressions as pharma brands generated significant coverage from ...

Global oncology portfolio sales were $1.7 billion, up 12%. Imbruvica sales were $848 million, down 6%. Venclexta sales were $655 million, up 11%. Elahere revenues were $148 million.

Skyrizi (risankizumab) is the first IL-23-selective drug to be cleared for the inflammatory bowel disease – ahead of rivals like Johnson & Johnson's Tremfya (guselkumab), and Sun Pharma's Ilumya ...

But over time, your decision to buy or sell a company’s stock should be based on what you believe will happen in the future.